MDM2-p53 Pathway Status in Clinical Samples of Well-Differentiated and Dedifferentiated Liposarcoma.

被引：0
|
作者：
Kumagai, A.
Motoi, T.
Yoshida, A.
Imamura, T.
Fukusato, T.
机构：
[1] Teikyo Univ, Sch Med, Tokyo 173, Japan
[2] Univ Tokyo, Tokyo, Japan
[3] Teikyo Univ Hosp, Tokyo, Japan
来源：
MODERN PATHOLOGY | 2011年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
56
引用
收藏
页码：17A / 17A
页数：1
相关论文
共 50 条
  • [1] MDM2-p53 Pathway Status in Clinical Samples of Well-Differentiated and Dedifferentiated Liposarcoma
    Kumagai, A.
    Motoi, T.
    Yoshida, A.
    Imamura, T.
    Fukusato, T.
    LABORATORY INVESTIGATION, 2011, 91 : 17A - 17A
  • [2] Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
    Traweek, Raymond S. S.
    Cope, Brandon M. M.
    Roland, Christina L. L.
    Keung, Emily Z. Z.
    Nassif, Elise F. F.
    Erstad, Derek J. J.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] MDM2 Copy Numbers in Well-Differentiated and Dedifferentiated Liposarcoma
    Ware, Patrick L.
    Snow, Anthony N.
    Gvalani, Maya
    Pettenati, Mark J.
    Qasem, Shadi A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (03) : 334 - 341
  • [4] Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Ray-Coquard, Isabelle
    Blay, Jean-Yves
    Italiano, Antoine
    Le Cesne, Axel
    Penel, Nicolas
    Zhi, Jianguo
    Heil, Florian
    Rueger, Ruediger
    Graves, Bradford
    Ding, Meichun
    Geho, David
    Middleton, Steven A.
    Vassilev, Lyubomir T.
    Nichols, Gwen L.
    Binh Nguyen Bui
    LANCET ONCOLOGY, 2012, 13 (11): : 1133 - 1140
  • [5] Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma:: Special emphasis on the distinct immunophenotype of the well-differentiated component
    Adachi, T
    Oda, Y
    Sakamoto, A
    Saito, T
    Tamiya, S
    Masuda, I
    Tsuneyoshi, M
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2001, 9 (02) : 99 - 109
  • [6] Phase 2 trial of the novel multi-receptor tyrosine kinase inhibitor sitravatinib in well-differentiated/dedifferentiated liposarcoma.
    Ingham, Matthew
    Lee, Shing Mirn
    Patwardhan, Parag
    Choy, Edwin
    Chen, Isan
    Singh-Kandah, Shahnaz
    Taiclet, Lauren
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] DEGREE OF MDM2 AMPLIFICATION AFFECTS CLINICAL OUTCOMES IN DEDIFFERENTIATED LIPOSARCOMA.
    Seligson, N. D.
    Bill, K. L. J.
    Hays, J. L.
    Demoret, B.
    Stets, C. W.
    Duggan, M.
    Bupathi, M.
    Shakya, R.
    Timmers, C.
    Walely, P. E.
    Pollock, R. E.
    Chen, J. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S38 - S38
  • [8] The MDM2-p53 pathway revisited
    Nag, Subhasree
    Qin, Jiangjiang
    Srivenugopal, Kalkunte S.
    Wang, Minghai
    Zhang, Ruiwen
    JOURNAL OF BIOMEDICAL RESEARCH, 2013, 27 (04): : 254 - 271
  • [9] The MDM2-p53 pathway revisited
    Subhasree Nag
    Jiangjiang Qin
    Kalkunte S.Srivenugopal
    Minghai Wang
    Ruiwen Zhang
    TheJournalofBiomedicalResearch, 2013, 27 (04) : 254 - 271
  • [10] Prognostic impact of the MDM2/HMGA2 ratio and clinicopathological factors in well-differentiated and dedifferentiated liposarcoma
    Yamashita, Kyoko
    Kohashi, Kenichi
    Yamada, Yuichi
    Akatsuka, Shinya
    Oda, Yoshinao
    MODERN PATHOLOGY, 2019, 32
12345